Cognizant, a global IT company and provider of digital solutions for the health science and pharma industries, recently announced that it has signed a multi-year agreement with Organon, a global pharmaceutical company (originally formed through a spinoff by Merck) that focuses on women’s health and provides more than 60 medicines in areas including reproductive health, dermatology, and more. Through the agreement, Cognizant will help scale Organon’s healthcare business by delivering industrial technology support for Organon’s global pharmaceutical manufacturing sites. The partnership will work to:
To discuss the partnership and how the technology Cognizant is providing will help solve supply chain issues for Organon, Pharma Commerce spoke to Surya Gummadi, Cognizant's SVP of global health sciences and SVP Americas.
Surya Gummadi: Cognizant will help scale Organon’s healthcare business by delivering full-stack industrial technology support for the company’s global pharmaceutical manufacturing sites in the United Kingdom, the Netherlands, Belgium, and Indonesia.
This includes managing Organon’s manufacturing systems with SAP’s S/4 HANA enterprise application suite. Additionally, by providing remote and onsite support teams to increase real-time visibility of the manufacturing process and ensure pharmaceutical development continuity, Cognizant will help Organon enhance supply chain oversight, increase medicinal yields, reduce cycle times and get products to patients faster.
Cognizant will begin with two parallel workstreams.
For Organon, technology is a key pillar of differentiation in fulfilling the mission of becoming the world’s leading women’s health company. With local and global project teams, Cognizant will continue to enhance Organon’s connectivity journey—connecting local and global systems.
Similarly, the continuing connectivity journey of connecting the shop floor systems to global systems such as S/4 HANA will provide near real time information about the supply chain and the progress of medicinal products through the manufacturing facilities.
The reach of the partnership is truly global, with its four major pharmaceutical manufacturing sites in Europe and Indonesia. The technology priorities focus on Organon’s manufacturing systems with SAP’s S/4 HANA enterprise application suite.
Growing local teams, with the right skills and the local language, will be critical to achieving the partnership goals. The blend of local and global teams to support the manufacturing systems will bring benefits in terms of quality and total cost of service.
We expect that the unique insights and understanding that will come from working inside the factory with Organon staff will drive a heightened level of overall service excellence and help Cognizant meet or exceed the goals of the partnership.
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.